Introduction {#sec1-1753425919887411}
============

Polymorphonuclear neutrophils (PMNs) are extremely important response cells of the innate immune system in humans. They represent the first line of defense against invading pathogens (e.g., bacteria and fungi) and have the most important role in the acute inflammatory response.^[@bibr1-1753425919887411],[@bibr2-1753425919887411]^ They are the most abundant blood leukocytes and have a very short lifecycle (24--48 h in the peripheral circulation and 1--4 d in tissue). The number of PMNs renewed daily in peripheral blood is about 0.8--1.6 × 10^9^ cells/kg body mass.^[@bibr1-1753425919887411],[@bibr3-1753425919887411]^

"Neutrophilia" refers to an abnormal increase in the number of mature neutrophils. Neutrophilia is the most common cause of leukocytosis, and is often associated with bacterial infection and some hematologic diseases (e.g., leukemia and polycythemia vera (PV)).^[@bibr4-1753425919887411]^

Increasing the number of PMNs is essential to attack invading pathogens, but increasing their number in an inappropriate manner can cause tissue damage.^[@bibr1-1753425919887411],[@bibr2-1753425919887411]^ Several intracellular and extracellular modulators can regulate the neutrophil count. For instance, intracellular cAMP can activate protein kinase A (PKA) and increase the number of neutrophils by reducing apoptosis and prolonging neutrophil survival through downstream signaling of PKA.^[@bibr5-1753425919887411]^ Caspases can increase PMN death by a cascade reaction, DNA cleavage, and protein kinase C delta (PKC-δ) activation.^[@bibr6-1753425919887411]^ Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and red blood cells, as anti-apoptotic factors, are extracellular modulators. GM-CSF can increase the number of neutrophils by up-regulating anti-apoptotic pathways such as phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and subsequently regulating the gene expression of several other apoptosis-related factors.^[@bibr1-1753425919887411],[@bibr3-1753425919887411]^

Neutrophilia is a common manifestation of sepsis, PV, or healthy neutrophils stimulated by GM-CSF or PKA agonists. Microarray analysis has revealed that some genes and pathways can regulate the number of neutrophils. Nevertheless, thorough analysis of differential expression of the key genes and pathways involved in neutrophilia has not been carried out. In this work, we analyzed three microarray datasets using multiple methods synergistically to identify key differentially expressed genes (DEGs) and pathways and revealed additional further molecular mechanisms involved in neutrophilia.

As machine-learning technology has entered bioinformatics, several computational methods have been developed to predict the functions of genes,^[@bibr7-1753425919887411]^ protein--protein interactions,^[@bibr8-1753425919887411]^ microbe--disease associations,^[@bibr9-1753425919887411]^ microbe--drug associations,^[@bibr10-1753425919887411]^ and drug--target interactions.^[@bibr11-1753425919887411]^ Through the corresponding bioinformatics tools, we wished to reveal further the molecular mechanisms of neutrophilia. We analyzed the key genes and pathways expressed differentially in PV and healthy neutrophils stimulated by GM-CSF, as well as the PKA agonists associated with neutrophilia, using systematic and integrated bioinformatics analysis.

Materials and methods {#sec2-1753425919887411}
=====================

Microarray data {#sec3-1753425919887411}
---------------

Expression of the genes in samples associated with sepsis, myeloproliferative neoplasms (MPNs), or healthy neutrophils stimulated by GM-CSF or a PKA agonist (GSE64457,^[@bibr12-1753425919887411]^ GSE54644,^[@bibr13-1753425919887411]^ or GSE94923^5^) from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)) was measured.

Neutrophilia samples were screened for analyses. GSE64457 and GSE94923 datasets were sequenced on the platform of the GeneChip Human Genome U133 Plus 2.0 Array (GPL570; Affymetrix, Santa Clara, CA, USA). GSE54644 was sequenced on the platform of the GeneChip HT-HG_U133A Early Access Array (GPL4685; Affymetrix).

GSE64457 comprised 15 samples from patients suffering from septic shock and eight samples of healthy neutrophils. According to the clinical data of patients detailed by Demaret and colleagues,^[@bibr12-1753425919887411]^ all the 15 patients with septic shock had a white blood cell count \>12,000/mm^3^, and their neutrophil count was increased significantly compared with that of healthy individuals. In our study, nine human-neutrophil samples were screened from GSE94923: three samples underwent 4-h incubation with GM-CSF; three samples underwent treatment with a PKA agonist; and three samples were unstimulated.

GSE54644 contained samples from 28 patients with PV and 11 samples of healthy granulocytes. Thomas and colleagues demonstrated that \< 5% of contaminating leukocytes contribute very little to the overall gene-expression profile of neutrophils in neutrophil preparations.^[@bibr14-1753425919887411]^ Most granulocytes are neutrophils, so we used the data from GSE54644. All the gene-expression data of our study were downloaded from a public database. [Table 1](#table1-1753425919887411){ref-type="table"} lists the information of the samples that we used.

###### 

Samples used in our study.

![](10.1177_1753425919887411-table1)

             Experimental group                                                                                                                                                                                                                                                                                                                               Control group
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------
  GSE64457   GSM1571528, GSM1571529, GSM1571530, GSM1571531, GSM1571532, GSM1571533, GSM1571534, GSM1571535, GSM1571536, GSM1571537, GSM1571538, GSM1571539, GSM1571540, GSM1571541, GSM1571542                                                                                                                                                               GSM1571543, GSM1571544, GSM1571545, GSM1571546, GSM1571547, GSM1571548, GSM1571549, GSM1571550
  GSE94923   GSM2492004, GSM2492005, GSM2492006, GSM2492016, GSM2492017, GSM2492018                                                                                                                                                                                                                                                                           GSM2492013, GSM2492014, GSM2492015
  GSE54644   GSM1320525, GSM1320529, GSM1320530, GSM1320533, GSM1320534, GSM1320541, GSM1320544, GSM1320546, GSM1320549, GSM1320550, GSM1320555, GSM1320556, GSM1320560, GSM1320561, GSM1320562, GSM1320564, GSM1320565, GSM1320568, GSM1320569, GSM1320571, GSM1320573, GSM1320574, GSM1320575, GSM1320577, GSM1320578, GSM1320584, GSM1320592, GSM1320593   GSM1320617, GSM1320618, GSM1320619, GSM1320620, GSM1320621, GSM1320622, GSM1320623, GSM1320624, GSM1320625, GSM1320626, GSM1320627

Data preprocessing and screening of DEGs {#sec4-1753425919887411}
----------------------------------------

Raw data were processed in R v3.5.0 ([www.r-project.org](http://www.r-project.org)). The Affy package ([www.bioconductor.org/packages/release/bioc/html/affy.html](http://www.bioconductor.org/packages/release/bioc/html/affy.html))^[@bibr15-1753425919887411]^ and the impute package ([www.bioconductor.org/packages/release/bioc/html/impute.html](http://www.bioconductor.org/packages/release/bioc/html/impute.html))^[@bibr16-1753425919887411]^ were utilized to process data, including background adjustment based on the robust multi-array average (RMA) algorithm, data normalization, and processing of missing values. We transformed the probe name of each series matrix into a gene symbol based on the corresponding annotation files of the Affy probe, and then filtered the DEGs of each dataset into R software using the limma package ([www.bioconductor.org/packages/release/bioc/html/limma.html](http://www.bioconductor.org/packages/release/bioc/html/limma.html))^[@bibr17-1753425919887411]^ by constructing a comparison model and the Bayes test. The limma package is a reliable choice for DEG discovery through analyses of DEGs of microarray datasets. It uses a particular class of statistical methods ("parametric empirical Bayes") that has been demonstrated to be particularly advantageous in experiments with small sample sizes, thereby ensuring that inference is reliable and stable even if the number of replicates is small.^[@bibr17-1753425919887411]^ DEGs were defined with a cut-off of *P* \< 0.05, which was adjusted using the method of Benjamini and Hochberg using a false discovery rate (FDR)^[@bibr18-1753425919887411]^ and fold-change \> 2. Subsequently, we screened the intersection of DEGs from every two datasets using an "up-regulated" group and a "down-regulated" group, respectively.

Hierarchical clustering analysis {#sec5-1753425919887411}
--------------------------------

Hierarchical clustering analysis can group similar elements in a binary tree. Using the gplots^[@bibr19-1753425919887411]^ and RColorBrewer^[@bibr20-1753425919887411]^ packages in R software, expression of the DEGs in each dataset was extracted for hierarchical clustering analysis, and then visualized in heatmaps.

The intersections of up-regulated or down-regulated DEGs from every two datasets were considered as candidate DEGs for advanced analyses. Gene Ontology (GO) and pathway enrichment of candidate DEGs were analyzed using up-regulated candidate DEGs and down-regulated candidate DEGs, respectively, employing multiple online databases and software: DAVID v6.7 (<https://david-d.ncifcrf.gov/>),^[@bibr7-1753425919887411],[@bibr21-1753425919887411]^ PANTHER v13.1 ([www.pantherdb.org](http://www.pantherdb.org)),^[@bibr22-1753425919887411]^ Reactome (<http://reactome.org>),^[@bibr23-1753425919887411]^ and the ReactomeFIPlugIn application^[@bibr24-1753425919887411],[@bibr25-1753425919887411]^ in Cytoscape v3.6.1.^[@bibr26-1753425919887411]^ DAVID, PANTHER, and Reactome are online databases providing many functional annotation tools for investigators to understand the biological importance behind a long list of genes. The *P* value for the significance of the gene-enrichment term listed by DAVID was examined with a modified Fisher's exact test,^[@bibr7-1753425919887411]^ whereas that for PANTHER and Reactome was obtained through over-representation analysis by Fisher's exact test,^[@bibr22-1753425919887411],[@bibr23-1753425919887411]^ and the results were corrected for the FDR using the Benjamini--Hochberg method. In addition, based on a binomial test, the ReactomeFIPlugIn application undertook pathway enrichment analysis on a list of genes.^[@bibr25-1753425919887411]^ Synergetic analysis was conducted using results with an FDR \< 0.05, *P* \< 0.05, and gene count \>2.

Construction of a protein--protein interaction (PPI) network {#sec6-1753425919887411}
------------------------------------------------------------

The interaction network among proteins encoded by candidate DEGs was researched by importing all the candidate DEGs into the STRING database v10.5 (<http://string-db.org>)^[@bibr27-1753425919887411]^ and calculating it online. Then, the STRING network was loaded into Cytoscape for analysis of hub genes using the CytoHubba application v0.1.^[@bibr28-1753425919887411]^ CytoHubba provides 12 analytical methods to identify hub objects and sub-networks from a complex interactome.^[@bibr28-1753425919887411]^ We extracted the top 30 results analyzed by these 12 methods. Then, we counted the frequency of the genes that appeared together in ≥ 5 methods: 34 genes were documented. Finally, we calculated the mass of each of these 34 genes and visualized a PPI network of proteins encoded by the top 29 genes by mass in Cytoscape. Conversely, up-regulated candidate DEGs, down-regulated candidate DEGs, and all candidate DEGs were loaded in Cytoscape for functional interaction (FI) gene-set analysis using the ReactomeFIPlugIn application (version 2017).^[@bibr25-1753425919887411]^ Subsequently, we obtained the PPI network. Next, we calculated and visualized hub genes using CytoHubba in Cytoscape through the maximal clique centrality (MCC) method (one of the 12 methods mentioned above).

Results {#sec7-1753425919887411}
=======

Screening of DEGs {#sec8-1753425919887411}
-----------------

Using *P* \< 0.05 and fold-change \>2 as cut-off criteria, we had gained 766 (366 up-regulated and 400 down-regulated), 982 (259 up-regulated and 723 down-regulated), and 539 (394 up-regulated and 145 down-regulated) DEGs from the expression-profile datasets GSE64457, GSE94923, and GSE54644, respectively (online Supplemental File S1). After ascertaining the intersection of DEGs from the up-regulated-DEGs group and the down-regulated-DEGs group from each of the two datasets, we screened 110 up-regulated DEGs and 108 down-regulated DEGs as candidate DEGs for advanced analyses ([Figure 1](#fig1-1753425919887411){ref-type="fig"} and [Table 2](#table2-1753425919887411){ref-type="table"}). Moreover, in the intersection of three datasets, there were 13 up-regulated DEGs (*IL18R1*, *ATP13A3*, *CD44*, *LAIR1*, *ATP6V1C1*, *ATP11B*, *ADAM9*, *IL6ST*, *LDLR*, *EXOSC4*, *IL18RAP*, *PPA2*, and *HES1*) and five down-regulated DEGs (*FCMR*, *SET*, *NOV*, *FGL2*, and *TSPAN13*).

![Intersection of (a) up-regulated DEGs and (b) down-regulated DEGs.](10.1177_1753425919887411-fig1){#fig1-1753425919887411}

###### 

Candidate DEGs screened for advanced analysis: 110 up-regulated and 108 down-regulated DEGs (gene names are shown in alphabetical order).

![](10.1177_1753425919887411-table2)

  Candidate DEGs   Gene name
  ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Up-regulated     *ADAM9, AGFG1, ANXA1, ARFGEF1, ARG1, ASPH, ATP11B, ATP13A3, ATP1B3, ATP6V1C1, ATP9A, C3AR1, CAPG, CAST, CCDC71L, CD177, CD24, CD44, CDK5RAP2, CSNK1A1, CST7, CYP1B1, DSC2, EGR1, ENO1, ETS2, EXOSC4, EXT1, F5, FKBP5, FOXQ1, FRMD4B, FUT4, GADD45A, GCLM, GK, GRB10, GRPEL1, GYG1, HES1, HK3, HP, HPGD, HS3ST3B1, HSD17B4, IL10RB-AS1, IL15, IL18R1, IL18RAP, IL1R2, IL6ST, IRAK3, ITGA7, IVNS1ABP, KIAA0930, KLF10, LAIR1, LARP1, LDLR, LILRA5, LIMS1, LRRC75A-AS1, MAP2K6, MAPK14, MAPK6, MAT2A, MCEMP1, MCOLN1, MEF2A, MGC12916, MSL3, MTRR, MYL12A, NAB1, NAIP, NFKBIZ, NRIP3, PCMT1, PDGFC, PFKFB2, PHF20L1, PHLDA1, PHTF1, PKM, PLAC8, PLSCR1, PNPLA6, POR, PPA2, PRKCE, PRNP, QSOX1, RAB20, RNF146, SERPINB1, SERPINB8, SGMS2, SGSH, SLC2A3, SMPDL3A, SYNE1, TES, TLK1, TLR4, TPK1, UBE2J1, UPP1, VNN1, WSB1, ZEB2*
  Down-regulated   *ADK, AKT1, ANGPT1, ARL5A, ARRB1, BAG4, BCLAF1, BRI3BP, BTN3A1, C14orf159, C5orf56, C9orf91, CASS4, CBFA2T3, CCDC146, CDK19, CHI3L1, CHST11, CNOT6L, COPS3, CTSS, CXCL6, CYB561, CYSLTR1, DCUN1D1, DDX28, DICER1, DOCK5, DTX4, DYRK2, ERCC1, ERV3-2, FAM117B, FAM174A, FCMR, FGL2, FLVCR1-AS1, FMNL3, FRY, FUNDC1, GAB1, GSE1, HCG27, HCRP1, HEY1, HVCN1, IMPA2, ITGA4, JAK1, JPX, KRBOX4, LOC101928893, LOC105371602, MED25, MPEG1, MPZL1, MSRB2, NFIC, NHS, NOV, NUDT3, NUP50-AS1, OGFRL1, OR52K3P, P2RY10, PARP8, PCGF5, PKN2, PLEKHG3, PPP1R12B, PRKAG2, RABGAP1L, RPAP3, RPGRIP1, RPS16P5, RPS6KA5, RUBCN, SET, SLC9A7, SPDYE1, SPECC1, SSPN, ST6GALNAC2, ST8SIA4, STK4, SUPT20H, TAF4, TATDN3, TCP11L2, TIGD3, TIMM23, TMCC1, TOPORS, TRANK1, TRERF1, TREX1, TRIM13, TRIOBP, TSPAN13, TTC22, UBR2, VPS41, WBP11, WLS, YEATS2, ZNF117, ZNF585A, ZNF652*

Hierarchical clustering analysis of DEGs {#sec9-1753425919887411}
----------------------------------------

Hierarchical clustering analysis was conducted for DEGs after ascertaining expression of the DEGs ([Figure 2](#fig2-1753425919887411){ref-type="fig"}). As shown in the heatmaps of [Figure 2](#fig2-1753425919887411){ref-type="fig"}, the DEGs of three datasets could clearly distinguish experimental samples from control samples.

![Heatmaps of the three GEO datasets.](10.1177_1753425919887411-fig2){#fig2-1753425919887411}

GO and pathway enrichment analysis of candidate DEGs {#sec10-1753425919887411}
----------------------------------------------------

Using multiple online databases and software (DAVID, PANTHER, Reactome, and ReactomeFIPlugIn application in Cytoscape), the GO and pathway enrichment of candidate DEGs were analyzed synergistically. The results before integration contained "biological process," "cellular component," "molecular function," and "pathway." The first three terms were analyzed by DAVID, PANTHER, and Reactome FI node function analysis in Cytoscape, and the pathway enrichment was analyzed by PANTHER, Reactome, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in DAVID, and Reactome FI node function analysis in Cytoscape. The top 15 integrated results were visualized and are listed in [Figures 3](#fig3-1753425919887411){ref-type="fig"} [](#fig4-1753425919887411){ref-type="fig"}to [5](#fig5-1753425919887411){ref-type="fig"} and [Table 3](#table3-1753425919887411){ref-type="table"}, and detailed results are shown in online Supplemental File S2.

![Top 15 integrated results of gene ontology and pathway enrichment analyses using all candidate DEGs.](10.1177_1753425919887411-fig3){#fig3-1753425919887411}

![Top 15 integrated results of gene ontology and pathway enrichment analyses using up-regulated candidate DEGs.](10.1177_1753425919887411-fig4){#fig4-1753425919887411}

![Top 15 integrated results of gene ontology and pathway enrichment analyses using down-regulated candidate DEGs.](10.1177_1753425919887411-fig5){#fig5-1753425919887411}

###### 

Top 15 GO terms and pathways enriched for DEGs.

![](10.1177_1753425919887411-table3)

  Category                  Term                                                                                      Count   P               Genes
  ------------------------- ----------------------------------------------------------------------------------------- ------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rectome FI BP All         IL-18-mediated signaling pathway                                                          3       1.74 × 10^−6^   *IL18RAP, AKT1, IL18R1*
  Rectome FI BP All         Apoptotic process                                                                         11      8.80 × 10^−6^   *ARRB1, PHLDA1, MEF2A, PRKCE, PLSCR1, STK4, BCLAF1, MAP2K6, GADD45A, MAPK14, PKN2*
  Rectome FI BP All         Protein phosphorylation                                                                   10      1.06 × 10^−5^   *PRKAG2, RPS6KA5, AKT1, JAK1, PRKCE, IRAK3, STK4, CDK19, CSNK1A1, PKN2*
  Rectome FI BP All         LPS-mediated signaling pathway                                                            4       1.25 × 10^−5^   *AKT1, PRKCE, TLR4, MAPK14*
  Rectome FI BP All         Intracellular signal transduction                                                         9       1.62 × 10^−5^   *PRKAG2, RPS6KA5, AKT1, JAK1, WSB1, PRKCE, STK4, MAPK14, PKN2*
  DAVID BP Up               Sulfur compound biosynthetic process                                                      6       2.17 × 10^−5^   *TPK1, MAT2A, EXT1, GCLM, HS3ST3B1, MTRR*
  PANTHER BP Up             Glycolysis                                                                                4       2.31 × 10^−5^   *HK3, ENO1, PFKFB2, PKM*
  Rectome FI BP All         Positive regulation of peptidyl-serine phosphorylation                                    5       2.59 × 10^−5^   *ARRB1, AKT1, CD44, STK4, ANGPT1*
  DAVID BP All              Sulfur compound biosynthetic process                                                      7       2.76 × 10^−5^   *TPK1, MAT2A, CHST11, EXT1, GCLM, HS3ST3B1, MTRR*
  PANTHER BP Up             Phosphate-containing compound metabolic process                                           22      2.98 × 10^−5^   *RAB20, MAPK14, ATP6V1C1, ATP11B, HK3, SGMS2, CSNK1A1, PRKCE, ATP9A, TPK1, PDGFC, MAPK6, GK, SGSH, IRAK3, GADD45A, GRPEL1, ARFGEF1, ATP1B3, MAP2K6, PPA2, PKM*
  Rectome FI BP All         Peptidyl-serine phosphorylation                                                           6       3.21 × 10^−5^   *AKT1, PRKCE, STK4, CSNK1A1, MAPK14, PKN2*
  Rectome FI BP Up          LPS-mediated signaling pathway                                                            3       4.00 × 10^−5^   *PRKCE, MAPK14, TLR4*
  Rectome FI BP All         IL-1-mediated signaling pathway                                                           3       4.55 × 10^−5^   *RPS6KA5, IRAK3, EGR1*
  Rectome FI BP Up          Apoptotic process                                                                         7       5.11 × 10^−5^   *PHLDA1, MAP2K6, MEF2A, GADD45A, PRKCE, MAPK14, PLSCR1*
  Rectome FI BP Up          IL-18-mediated signaling pathway                                                          2       5.34 × 10^−5^   *IL18RAP, IL18R1*
  Rectome FI MF All         Protein serine/threonine kinase activity                                                  9       1.26 × 10^−5^   *RPS6KA5, AKT1, PRKCE, IRAK3, STK4, MAP2K6, CSNK1A1, MAPK14, PKN2*
  PANTHER MF All            Catalytic activity                                                                        70      1.53 × 10^−5^   *CTSS, RAB20, MAPK14, DYRK2, ATP6V1C1, P2RY10, DTX4, POR, GYG1, TRIOBP, FKBP5, ATP11B, PRKAG2, HK3, SGMS2, PPP1R12B, PCMT1, HP, IMPA2, CSNK1A1, QSOX1, TLK1, CDK19, PRKCE, UPP1, CNOT6L, ATP9A, PNPLA6, CHST11, ARG1, NOV, MTRR, TPK1, CYSLTR1, PDGFC, CYB561, MAPK6, AKT1, GK, SGSH, CHI3L1, NUDT3, ENO1, PFKFB2, C3AR1, MAT2A, IRAK3, VNN1, GADD45A, RABGAP1L, GRPEL1, ARFGEF1, ATP1B3, SET, DICER1, SPDYE1, PARP8, MAP2K6, FUT4, PKN2, EXT1, GCLM, STK4, RPGRIP1, ERCC1, DCUN1D1, MSRB2, TOPORS, PPA2, PKM*
  PANTHER MF Up             Transferase activity                                                                      20      2.09 × 10^−5^   *GYG1, HK3, SGMS2, PCMT1, CSNK1A1, TLK1, PRKCE, UPP1, TPK1, MAPK14, PDGFC, MAPK6, GK, MAT2A, IRAK3, GADD45A, MAP2K6, FUT4, EXT1, PKM*
  PANTHER MF All            Kinase activity                                                                           19      3.00 × 10^−5^   *MAPK14, DYRK2, PRKAG2, HK3, CSNK1A1, TLK1, CDK19, PRKCE, PDGFC, MAPK6, AKT1, GK, IRAK3, GADD45A, SPDYE1, MAP2K6, PKN2, STK4, PKM*
  PANTHER MF All            Protein kinase activity                                                                   15      3.19 × 10^−5^   *MAPK14, DYRK2, CSNK1A1, TLK1, CDK19, PRKCE, PDGFC, MAPK6, AKT1, IRAK3, GADD45A, SPDYE1, MAP2K6, PKN2, STK4*
  PANTHER MF Up             Catalytic activity                                                                        41      4.02 × 10^−5^   *RAB20, MAPK14, ATP6V1C1, POR, GYG1, FKBP5, ATP11B, HK3, SGMS2, PCMT1, HP, CSNK1A1, QSOX1, TLK1, PRKCE, UPP1, ATP9A, PNPLA6, ARG1, MTRR, TPK1, PDGFC, MAPK6, GK, SGSH, ENO1, PFKFB2, C3AR1, MAT2A, IRAK3, VNN1, GADD45A, GRPEL1, ARFGEF1, ATP1B3, MAP2K6, FUT4, EXT1, GCLM, PPA2, PKM*
  PANTHER MF All            Transferase activity                                                                      29      1.09 × 10^−4^   *MAPK14, DYRK2, GYG1, PRKAG2, HK3, SGMS2, PCMT1, CSNK1A1, TLK1, CDK19, PRKCE, UPP1, CHST11, TPK1, PDGFC, MAPK6, AKT1, GK, MAT2A, IRAK3, GADD45A, SPDYE1, PARP8, MAP2K6, FUT4, PKN2, EXT1, STK4, PKM*
  Rectome FI MF Up          IL-1 receptor activity                                                                    2       1.11 × 10^−4^   *IL1R2, IL18R1*
  PANTHER MF Up             Kinase activity                                                                           12      1.31 × 10^−4^   *MAPK14, HK3, CSNK1A1, TLK1, PRKCE, DGFC, APK6, GK, IRAK3, GADD45A, MAP2K6, PKM*
  Rectome FI MF All         ATP binding                                                                               15      2.25 × 10^−4^   *PRKAG2, HK3, RPS6KA5, AKT1, JAK1, PRKCE, IRAK3, PKM, PFKFB2, STK4, MAP2K6, CDK19, CSNK1A1, MAPK14, PKN2*
  Rectome FI MF Up          MAPK activity                                                                             2       3.80 × 10^−4^   *MAP2K6, MAPK14*
  PANTHER MF Up             Protein kinase activity                                                                   9       3.93 × 10^−4^   *MAPK14, CSNK1A1, TLK1, PRKCE, PDGFC, MAPK6, IRAK3, GADD45A, MAP2K6*
  Rectome FI MF All         Kinase activity                                                                           4       4.13 × 10^−4^   *AKT1, PKM, CSNK1A1, PKN2*
  Rectome FI MF All         IL-1 receptor activity                                                                    2       5.01 × 10^−4^   *IL1R2, IL18R1*
  DAVID MF Up               ATPase activity, coupled with transmembrane movement of ions, phosphorylative mechanism   5       5.09 × 10^−4^   *ATP6V1C1, ATP1B3, ATP9A, ATP11B, ATP13A3*
  Rectome FI CC All         Nucleus                                                                                   31      1.98 × 10^−4^   *ARRB1, ETS2, RPS6KA5, NFKBIZ, AKT1, PHLDA1, JAK1, KLF10, MEF2A, ARG1, PRKCE, IRAK3, CBFA2T3, PLSCR1, PKM, PFKFB2, DCUN1D1, UBR2, STK4, BCLAF1, GRPEL1, PDGFC, MAP2K6, EGR1, CDK19, GADD45A, MAPK14, COPS3, NFIC, PKN2, ZNF652*
  Rectome FI CC All         Cytosol                                                                                   31      3.84 × 10^−4^   *PRKAG2, ARRB1, ETS2, HK3, GRB10, AKT1, PHLDA1, JAK1, MEF2A, WSB1, IL15, ARG1, PRKCE, GAB1, PLSCR1, PKM, PPP1R12B, CD44, PFKFB2, DCUN1D1, UBR2, STK4, MYL12A, PDGFC, MAP2K6, CDK19, CSNK1A1, MAPK14, COPS3, PKN2, LIMS1*
  DAVID CC All              Golgi apparatus                                                                           21      4.97 × 10^−4^   *SLC9A7, SGMS2, AGFG1, VPS41, IL15, CBFA2T3, ST6GALNAC2, SYNE1, CD44, ARRB1, ST8SIA4, CHST11, NAB1, PHTF1, FUT4, PDGFC, PRNP, EXT1, QSOX1, RAB20, HS3ST3B1*
  Rectome FI CC Up          Nuclear speck                                                                             5       6.15 × 10^−4^   *NFKBIZ, CSNK1A1, GADD45A, IL15, MAPK14*
  DAVID CC All              Golgi apparatus part                                                                      11      8.34 × 10^−4^   *SLC9A7, SGMS2, ARRB1, ST8SIA4, PHTF1, VPS41, PDGFC, CBFA2T3, EXT1, QSOX1, ST6GALNAC2*
  DAVID CC Up               Golgi apparatus                                                                           14      1.54 × 10^−3^   *AGFG1, SGMS2, IL15, SYNE1, CD44, NAB1, PHTF1, FUT4, PDGFC, EXT1, PRNP, QSOX1, RAB20, HS3ST3B1*
  Rectome FI CC Up          Secretory granule lumen                                                                   3       1.57 × 10^−3^   *HK3, MAPK14, PKM*
  Rectome FI CC Up          Ficolin-1-rich granule lumen                                                              3       1.97 × 10^−3^   *HK3, MAPK14, PKM*
  Rectome FI CC Up          Cell surface                                                                              5       2.33 × 10^−3^   *PDGFC, IL15, ITGA7, TLR4, CD44*
  DAVID CC All              Golgi membrane                                                                            8       2.90 × 10^−3^   *SGMS2, ARRB1, ST8SIA4, PDGFC, CBFA2T3, EXT1, QSOX1, ST6GALNAC2*
  DAVID CC Up               Endomembrane system                                                                       12      5.66 × 10^−3^   *SYNE1, CYP1B1, SGMS2, AGFG1, LDLR, ATP11B, PDGFC, ASPH, EXT1, QSOX1, PNPLA6, PHLDA1*
  DAVID CC All              Endomembrane system                                                                       17      5.78 × 10^−3^   *CYP1B1, SGMS2, AGFG1, LDLR, ATP11B, TREX1, CBFA2T3, ST6GALNAC2, PNPLA6, SYNE1, ARRB1, ST8SIA4, PDGFC, ASPH, EXT1, QSOX1, PHLDA1*
  DAVID CC Down             Golgi apparatus part                                                                      6       7.84 × 10^−3^   *SLC9A7, ARRB1, ST8SIA4, VPS41, CBFA2T3, ST6GALNAC2*
  DAVID CC All              Integral to organelle membrane                                                            6       8.37 × 10^−3^   *SGMS2, ST8SIA4, ASPH, EXT1, QSOX1, ST6GALNAC2*
  DAVID CC All              Integral to Golgi membrane                                                                4       9.43 × 10^−3^   *SGMS2, ST8SIA4, QSOX1, ST6GALNAC2*
  Rectome FI Pathway All    IL-6-mediated signaling events (N)                                                        6       8.42 × 10^−8^   *AKT1, JAK1, GAB1, IL6ST, MAP2K6, MAPK14*
  Rectome FI Pathway Up     IL-12-mediated signaling events (N)                                                       4       8.61 × 10^−6^   *IL18RAP, MAP2K6, MAPK14, IL18R1*
  Rectome FI Pathway Up     IL-1 family signaling (R)                                                                 5       9.64 × 10^−6^   *IL18RAP, MAP2K6, IL1R2, IRAK3, IL18R1*
  Rectome FI Pathway All    TNF-α signaling pathway (K)                                                               6       1.11 × 10^−5^   *RPS6KA5, AKT1, IL15, MAP2K6, MAPK14, IL18R1*
  Rectome FI Pathway Up     TLR cascades (R)                                                                          5       1.18 × 10^−5^   *MAP2K6, MEF2A, IRAK3, MAPK14, TLR4*
  Rectome FI Pathway Up     Cytokine--cytokine receptor interaction (K)                                               6       1.65 × 10^−5^   *IL18RAP, PDGFC, IL15, IL1R2, IL6ST, IL18R1*
  Rectome FI Pathway All    Trk receptor signaling mediated by the MAPK pathway (N)                                   4       1.69 × 10^−5^   *RPS6KA5, MAP2K6, EGR1, MAPK14*
  Rectome FI Pathway Up     Myogenesis (R)                                                                            3       1.93 × 10^−5^   *MAP2K6, MEF2A, MAPK14*
  Rectome FI Pathway All    MAPK signaling pathway (K)                                                                8       1.93 × 10^−5^   *ARRB1, RPS6KA5, AKT1, IL1R2, STK4, MAP2K6, GADD45A, MAPK14*
  Rectome FI Pathway Down   IL-6-mediated signaling events (N)                                                        3       2.06 × 10^−5^   *GAB1, AKT1, JAK1*
  Rectome FI Pathway All    CXCR3-mediated signaling events (N)                                                       4       2.13 × 10^−5^   *ARRB1, AKT1, MAP2K6, MAPK14*
  Rectome FI Pathway Up     p38 MAPK signaling pathway (N)                                                            3       2.74 × 10^−5^   *MAP2K6, GADD45A, MAPK14*
  Rectome FI Pathway All    TLR cascades (R)                                                                          6       4.80 × 10^−5^   *RPS6KA5, MEF2A, IRAK3, TLR4, MAP2K6, MAPK14*
  Rectome FI Pathway Up     Trk receptor signaling mediated by the MAPK pathway (N)                                   3       4.96 × 10^−5^   *MAP2K6, EGR1, MAPK14*
  Rectome FI Pathway Up     IL-1-mediated signaling events (N)                                                        3       5.42 × 10^−5^   *MAP2K6, IL1R2, IRAK3*

All: all candidate DEGs; BP: biological process; CC: cellular component; Down: down-regulated candidate DEGs; MF: molecular function; Up: up-regulated candidate DEGs.

As shown in [Table 3](#table3-1753425919887411){ref-type="table"}, the top five GO biological processes were "IL-18-mediated signaling pathway," "apoptotic process," "protein phosphorylation," "LPS-mediated signaling pathway," and "intracellular signal transduction." The top five GO molecular functions were "protein serine/threonine kinase activity," "catalytic activity," "transferase activity," "kinase activity," and "protein kinase activity.". The top five enriched pathways were "IL-6-mediated signaling events," "IL-12-mediated signaling events," "IL-1 family signaling," "TNF-α signaling pathway," and "TLR cascades." The *P* value of GO biological processes, molecular functions, and the enriched-pathway terms stated above was lower than 10^−5^.

Analyses of PPI networks and hub genes {#sec11-1753425919887411}
--------------------------------------

First, we imported all candidate DEGs into the STRING database, loaded the STRING network in Cytoscape, and calculated the hub genes using the methods mentioned above. We found that 112 DEGs (70 up-regulated and 42 down-regulated genes) of 218 candidate DEGs were filtered into the PPI network of DEGs and contained 112 nodes and 159 edges ([Figure 6a)](#fig6-1753425919887411){ref-type="fig"}. Also, 106 of those 218 candidate DEGs did not fall into the PPI network of DEGs. Subsequently, the top 29 hub genes were obtained using CytoHubba in Cytoscape by integrating the results analyzed by the 12 methods ([Figure 6b)](#fig6-1753425919887411){ref-type="fig"}.

![PPI networks and hub genes.](10.1177_1753425919887411-fig6){#fig6-1753425919887411}

Second, through Reactome FI gene-set analysis in Cytoscape, we obtained PPI networks that included 55 DEGs (32 up-regulated and 23 down-regulated genes) from all 218 candidate DEGs ([Figure 6c](#fig6-1753425919887411){ref-type="fig"}), 26 DEGs from 110 up-regulated candidate DEGs ([Figure 6d](#fig6-1753425919887411){ref-type="fig"}), and 15 DEGs from 108 down-regulated candidate DEGs ([Figure 6e)](#fig6-1753425919887411){ref-type="fig"}. The hub-gene analysis of those PPI networks was conducted, and the results are visualized in [Figure 6](#fig6-1753425919887411){ref-type="fig"}, with different colors in the corresponding octagon (representing up-regulated DEGs) or hexagon (representing down-regulated DEGs). Finally, using the results from [Figure 6](#fig6-1753425919887411){ref-type="fig"}, we listed the top 10 of those hub genes in [Table 4](#table4-1753425919887411){ref-type="table"}. The logFC and *P* value of the top 10 hub genes in [Table 4](#table4-1753425919887411){ref-type="table"} are shown in online Supplemental File S3.

###### 

Top 10 hub genes in [Figure 6](#fig6-1753425919887411){ref-type="fig"} (sorted by mass from large to small).

![](10.1177_1753425919887411-table4)

  PPI network                                           Gene name
  ----------------------------------------------------- ------------------------------------------------------------------------
  [Figure 6a](#fig6-1753425919887411){ref-type="fig"}   *AKT1, MAPK14, TLR4, EGR1, CNOT6L, JAK1, CD44, LDLR, IRAK3, ENO1*
  [Figure 6b](#fig6-1753425919887411){ref-type="fig"}   *AKT1, MAPK14, TLR4, CD44, JAK1, ENO1, ARRB1, LDLR, CNOT6L, EGR1*
  [Figure 6c](#fig6-1753425919887411){ref-type="fig"}   *JAK1, MAPK14, AKT1, IL6ST, GAB1, EGR1, MAP2K6, PRKCE, LIMS1, MEF2A*
  [Figure 6d](#fig6-1753425919887411){ref-type="fig"}   *EGR1, MAPK14, MAP2K6, POR, MEF2A, IL18RAP, IL1R2, IL6ST, IL18R1, PKM*
  [Figure 6e](#fig6-1753425919887411){ref-type="fig"}   *AKT1, JAK1, GAB1, DCUN1D1, COPS3, PRKAG2, ARRB1, PKN2, BCLAF1, MED25*

Taken together, these results showed that the most significant hub DEGs were *AKT1*, *MAPK14*, *JAK1*, *EGR1*, *TLR4*, *CNOT6L*, *CD44*, *LDLR*, *ENO1*, *ARRB1*, *IL6ST*, *GAB1*, and *MAP2K6* (sorted by the frequency of occurrence in [Table 4](#table4-1753425919887411){ref-type="table"} from 4 to 2). In addition, *CD44*, *LDLR*, *IL6ST*, *IL18RAP*, and *IL18R1* were present in both the top 10 of hub genes and the intersection of the three datasets.

Discussion {#sec12-1753425919887411}
==========

We screened DEGs by analyzing neutrophil samples that most probably showed neutrophilia as well as control samples from GSE64457, GSE94923, and GSE54644 datasets. As shown in the heatmaps obtained *via* hierarchical clustering analysis, the DEGs of these three datasets could clearly distinguish experimental samples from control samples. By intersecting DEGs from the up-regulated-DEGs group and down-regulated-DEGs group of every two datasets, we obtained 110 up-regulated DEGs and 108 down-regulated DEGs as candidate DEGs for analyses of GO, pathway enrichment, PPI networks, and hub genes.

Functional enrichment analysis showed that IL-mediated (IL-1, IL6, IL-12, and IL-18) signaling pathways, LPS-mediated signaling pathways,^[@bibr29-1753425919887411],[@bibr30-1753425919887411]^ TNF-α signaling pathways,^[@bibr31-1753425919887411],[@bibr32-1753425919887411]^ TLR cascades,^[@bibr33-1753425919887411],[@bibr34-1753425919887411]^ MAPK signaling pathways,^[@bibr32-1753425919887411],[@bibr35-1753425919887411],[@bibr36-1753425919887411]^ PI3K--Akt signaling pathways,^[@bibr36-1753425919887411][@bibr37-1753425919887411]--[@bibr38-1753425919887411]^ and biological processes or molecular functions (e.g., apoptotic process, protein phosphorylation, intracellular signal transduction, kinase activity, catalytic activity, and transferase activity) were involved in neutrophils when neutrophil counts were increased in peripheral blood.

Several studies have demonstrated that the pathways, biological processes, and molecular functions mentioned above are implicated in neutrophil apoptosis and the pathogenesis of inflammatory diseases, some autoimmune diseases, and hematologic diseases.^[@bibr29-1753425919887411][@bibr40-1753425919887411][@bibr41-1753425919887411][@bibr42-1753425919887411]--[@bibr43-1753425919887411]^ For example, IL-18 is a member of the IL-1 family and can be processed by caspase 1 to a biologically active mature form of size 18 kDa.^[@bibr43-1753425919887411]^ IL-1, IL6, IL-12, and IL-18 are pro-inflammatory cytokines that can promote the response of the immune system, induce local and systemic inflammation, and eliminate the microorganisms associated with tissue damage.^[@bibr39-1753425919887411],[@bibr41-1753425919887411][@bibr42-1753425919887411]--[@bibr43-1753425919887411]^ All these pro-inflammatory cytokines have been found to be involved in the pathogenesis or etiology of various infections, gout, rheumatoid arthritis, inflammatory-induced bone destruction, periodontitis, and other inflammatory or autoimmune diseases. The IL-1 family also has important roles in the pathogenesis of several myeloid and lymphoid hematologic malignancies.^[@bibr40-1753425919887411]^ Besides, therapeutic targeting of the IL-1 pathway in patients with hematologic malignancies, autoinflammatory diseases, gout, and cancer therapy--related complications has been studied recently.^[@bibr39-1753425919887411],[@bibr40-1753425919887411]^ IL-1 (as well as other cytokines or factors) may prove to be a very promising and useful target against diseases in the near future. Moreover, signaling pathways involving LPS,^[@bibr29-1753425919887411],[@bibr30-1753425919887411]^ TNF-α,^[@bibr31-1753425919887411],[@bibr32-1753425919887411]^ MAPK,^[@bibr32-1753425919887411],[@bibr35-1753425919887411]^ TLR,^[@bibr33-1753425919887411],[@bibr34-1753425919887411]^ and PI3K--Akt^[@bibr36-1753425919887411][@bibr37-1753425919887411]--[@bibr38-1753425919887411]^ have been shown to be associated with PMN apoptosis.

Analyses of PPI networks and hub genes revealed the most important hub DEGs to be *AKT1*, *MAPK14*, *JAK1*, *EGR1*, *TLR4*, *CNOT6L*, *CD44*, *LDLR*, *ENO1*, *ARRB1*, *IL6ST*, *GAB1*, and *MAP2K6*. Besides, *CD44*, *LDLR*, *IL6ST*, *IL18RAP*, and *IL18R1* were present in both the top 10 hub genes and the intersection of the three datasets. These genes may have important roles in inflammatory diseases as well as some autoimmune and hematologic diseases *via* the corresponding molecular functions or signaling pathways.^[@bibr30-1753425919887411],[@bibr44-1753425919887411][@bibr45-1753425919887411][@bibr46-1753425919887411][@bibr47-1753425919887411][@bibr48-1753425919887411][@bibr49-1753425919887411][@bibr50-1753425919887411][@bibr51-1753425919887411][@bibr52-1753425919887411][@bibr53-1753425919887411][@bibr54-1753425919887411][@bibr55-1753425919887411][@bibr56-1753425919887411][@bibr57-1753425919887411][@bibr58-1753425919887411][@bibr59-1753425919887411][@bibr60-1753425919887411]--[@bibr61-1753425919887411]^

In fact, some of these hub genes have been shown to be associated with such diseases because they influence the number of neutrophils by regulating the recruitment and apoptosis of neutrophils in peripheral blood or tissues.^[@bibr30-1753425919887411],[@bibr44-1753425919887411],[@bibr45-1753425919887411],[@bibr51-1753425919887411],[@bibr58-1753425919887411],[@bibr60-1753425919887411],[@bibr62-1753425919887411]^ Moreover, some of these genes have been utilized as therapeutic targets in inflammatory diseases as well as some autoimmune and hematologic diseases.^[@bibr49-1753425919887411],[@bibr50-1753425919887411],[@bibr55-1753425919887411],[@bibr56-1753425919887411],[@bibr59-1753425919887411],[@bibr61-1753425919887411],[@bibr63-1753425919887411]^

A study in mice by Liu and colleagues showed that protein kinase *AKT1* was the dominant isoform expressed in neutrophils and that its expression was down-regulated following bacterial infection and neutrophil activation.^[@bibr44-1753425919887411]^ The expression trend of *AKT1* in that study was in accordance with our results. The migration and bactericidal capacity of neutrophils with *AKT1* deficiency is enhanced in the acute inflammatory response and mechanistically. The *AKT1*--signal transducer and activator of transcription (STAT)1 signaling axis can negatively regulate the recruitment and activation of neutrophils in acute inflammatory lung injury and *Staphylococcus aureus* infection in mice.^[@bibr44-1753425919887411]^ However, Di Lorenzo and co-workers found that the loss of *AKT1 in vivo* reduced the microvascular permeability markedly, which could suppress neutrophil efflux and then decrease the number of PMNs in tissues.^[@bibr58-1753425919887411]^ Moreover, several studies have demonstrated that *AKT1* is involved in neutrophil apoptosis,^[@bibr45-1753425919887411]^ the inflammatory response,^[@bibr46-1753425919887411]^ and hematologic disease.^[@bibr47-1753425919887411]^ Consequently, the exact role of *AKT1* in neutrophils merits further research.

The JAK1 gene is a critical effector of signaling of pro-inflammatory cytokines. The proliferation and differentiation of neutrophils are regulated by granulocyte-specific colony-stimulating factor (G-CSF) through tyrosine phosphorylation and activation of *JAK1* and members of the SATA family.^[@bibr57-1753425919887411]^ Conversely, *JAK1* inhibitors can cause a reduction in the number of neutrophils and exert anti-inflammatory activity, and could be used against rheumatoid arthritis (RA) and other autoimmune diseases.^[@bibr56-1753425919887411]^ Indeed, abnormal activity of *JAK1* has been linked to immunologic and neoplastic diseases.^[@bibr48-1753425919887411]^ *JAK1* inhibitors have been applied against rheumatoid arthritis,^[@bibr49-1753425919887411],[@bibr61-1753425919887411]^ chronic neutrophilic leukemia,^[@bibr50-1753425919887411]^ and other immune-inflammatory diseases or hematologic diseases. Thus, *JAK1* may be a very promising and useful target for treating those diseases in the near future.

*MAPK14*, also known as p38, still has the greatest weight in the interactions shown in [Figure 6](#fig6-1753425919887411){ref-type="fig"}. The MAPKs act as integration points for multiple biochemical signals and are involved in the proliferation, differentiation, transcription regulation, and development of cells. Meanwhile, *MAPK14* has important roles in inflammatory diseases and could be a target for autoimmune and other diseases.^[@bibr59-1753425919887411]^ Some reports have suggested that p38 MAPK may be involved in the apoptosis and recruitment of neutrophils. For instance, through activation of the p38/MAPK pathway, 1,25-dihydroxyvitamin-D3 can promote neutrophil apoptosis in the peripheral blood of patients with type 2 diabetes mellitus and periodontitis,^[@bibr60-1753425919887411]^ whereas IL-33 can regulate cytokine production and neutrophil recruitment. However, the association between *MAPK14* and neutrophilia is incompletely understood and is an important issue for future research.

Besides, the number of PMNs could be regulated by other hub genes screened in our study. Murray and colleagues indicated that neutrophil apoptosis can be suppressed by TLR4 activation.^[@bibr30-1753425919887411]^ Several studies have demonstrated that the gene for cluster of differentiation (CD)44 is critically involved in neutrophil apoptosis,^[@bibr51-1753425919887411]^ inflammation,^[@bibr52-1753425919887411]^ and hematologic diseases.^[@bibr53-1753425919887411],[@bibr54-1753425919887411]^ Furthermore, anti-CD44 mAbs have been studied for treatment of the aggressive forms of chronic lymphocytic leukemia.^[@bibr55-1753425919887411]^

In summary, the reports mentioned above support the results of our bioinformatics study. Nevertheless, some molecules need to be validated and researched further, for example, using quantitative polymerase chain reactions. Although we identified several key genes and pathways, some may have been missed. Experimental verification of our findings is important.

Conclusions {#sec13-1753425919887411}
===========

A total of 218 candidate DEGs were studied using multiple online databases and software: DAVID, PANTHER, Reactome, ReactomeFIPlugIn, and CytoHubba in Cytoscape. *AKT1*, *MAPK14*, *JAK1*, *EGR1*, *TLR4*, *CNOT6L*, *CD44*, *LDLR*, *ENO1*, *ARRB1*, *IL6ST, GAB1*, *MAP2K6*, and other hub genes might cause neutrophilia and be implicated in the pathogenesis of inflammatory diseases, as well as some autoimmune and hematologic diseases, through various signaling pathways.

Our findings provide new insights into the pathogenesis of some diseases and lay the foundation for selection of targets related to the diagnosis, treatment, and prognosis of those diseases.
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